Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Retrovirus Life Cycles

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Do They, or Don't They? Integrase Strand Transfer Inhibitors, Tenofovir Alafenamide, and Excessive Weight Gain in People with HIV.

The Journal of infectious diseases·2026

Same author

Impact of COVID-19 Monoclonal Antibody Therapy on Subsequent Vaccine-elicited SARS-CoV-2 Immune Responses.

The Journal of infectious diseases·2026

Same author

A community and clinical collaboration to optimize HIV treatment and care for people with HIV in Australia-Solutions from the Beyond Undetectable symposium.

HIV medicine·2025

Same author

Implementing a Social Work-Led Hepatitis C Treatment Model for Individuals with Substance Use Disorders in Primary Care.

Journal of evidence-based social work (2019)·2025

Same author

Rapid Elimination of Culturable SARS-CoV-2 With Intramuscular or Intravenous Administration of Antiviral Monoclonal Antibody Therapy.

Open forum infectious diseases·2025

Same author

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial.

Contemporary clinical trials·2025

Search research articles

Related Experiment Video

Updated: Jul 11, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Considering metabolic issues when initiating HIV therapy.

David Alain Wohl¹

¹The University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC 27599, USA. wohl@med.unc.edu

Current HIV/AIDS Reports

|September 22, 2007

Summary

New clinical trials clarify the links between HIV antiretroviral therapies and metabolic complications like dyslipidemia and body fat changes. These findings challenge previous perceptions and inform safer HIV treatment choices.

More Related Videos

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood

Published on: August 12, 2016

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Related Experiment Videos

Last Updated: Jul 11, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood

A Simple Flow Cytometric Method to Measure Glucose Uptake and Glucose Transporter Expression for Monocyte Subpopulations in Whole Blood

Published on: August 12, 2016

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

Area of Science:

Infectious Diseases
Metabolic Medicine
Pharmacology

Background:

Patients with HIV infection face risks of metabolic complications with antiretroviral therapy.
Fear of metabolic consequences can impact treatment adherence and initiation.
Previous understanding of therapy-related metabolic issues was based on limited data and unsupported perceptions.

Purpose of the Study:

To objectively assess the relative contributions of specific antiretrovirals and their combinations to dyslipidemia and body fat changes.
To clarify the association between antiretroviral exposure and lipid and fat disorders.
To challenge and update existing perceptions regarding the causes of these metabolic complications.

Main Methods:

Comparative clinical trials were conducted over the past year.
Data from these trials were analyzed to evaluate associations between specific antiretroviral agents and metabolic outcomes.
Focus on dyslipidemia and body fat alterations.

Main Results:

Recent comparative trials have provided objective data on antiretroviral-associated metabolic complications.
Results have clarified the relationship between specific drug exposures and lipid/fat disorders.
Some findings challenge long-held, unsupported beliefs about therapy-metabolism links.

Conclusions:

Emerging clinical trial data offer a clearer understanding of metabolic risks associated with HIV therapies.
This evidence can help clinicians and patients make more informed treatment decisions.
Updated perceptions are crucial for managing metabolic health in HIV patients on antiretroviral treatment.